Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon Dewald, Marilyn L. Slovak, Elisabeth M. Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

Original languageEnglish (US)
Pages (from-to)2095-2101
Number of pages7
JournalMedical Oncology
Volume29
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Chromosome Aberrations
Tretinoin
Drug Therapy
Survival
Karyotype
Therapeutics
Retrospective Studies

Keywords

  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Karyotype
  • T(15;17)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). / Wiernik, Peter H.; Sun, Zhuoxin; Gundacker, Holly; Dewald, Gordon; Slovak, Marilyn L.; Paietta, Elisabeth M.; Kim, Haesook T.; Appelbaum, Frederick R.; Cassileth, Peter A.; Tallman, Martin S.

In: Medical Oncology, Vol. 29, No. 3, 09.2012, p. 2095-2101.

Research output: Contribution to journalArticle

Wiernik, PH, Sun, Z, Gundacker, H, Dewald, G, Slovak, ML, Paietta, EM, Kim, HT, Appelbaum, FR, Cassileth, PA & Tallman, MS 2012, 'Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)', Medical Oncology, vol. 29, no. 3, pp. 2095-2101. https://doi.org/10.1007/s12032-012-0251-7
Wiernik, Peter H. ; Sun, Zhuoxin ; Gundacker, Holly ; Dewald, Gordon ; Slovak, Marilyn L. ; Paietta, Elisabeth M. ; Kim, Haesook T. ; Appelbaum, Frederick R. ; Cassileth, Peter A. ; Tallman, Martin S. / Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). In: Medical Oncology. 2012 ; Vol. 29, No. 3. pp. 2095-2101.
@article{29d7e924ac834c619b558a801ed73e6b,
title = "Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)",
abstract = "This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.",
keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Karyotype, T(15;17)",
author = "Wiernik, {Peter H.} and Zhuoxin Sun and Holly Gundacker and Gordon Dewald and Slovak, {Marilyn L.} and Paietta, {Elisabeth M.} and Kim, {Haesook T.} and Appelbaum, {Frederick R.} and Cassileth, {Peter A.} and Tallman, {Martin S.}",
year = "2012",
month = "9",
doi = "10.1007/s12032-012-0251-7",
language = "English (US)",
volume = "29",
pages = "2095--2101",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

AU - Wiernik, Peter H.

AU - Sun, Zhuoxin

AU - Gundacker, Holly

AU - Dewald, Gordon

AU - Slovak, Marilyn L.

AU - Paietta, Elisabeth M.

AU - Kim, Haesook T.

AU - Appelbaum, Frederick R.

AU - Cassileth, Peter A.

AU - Tallman, Martin S.

PY - 2012/9

Y1 - 2012/9

N2 - This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

AB - This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Karyotype

KW - T(15;17)

UR - http://www.scopus.com/inward/record.url?scp=84872820174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872820174&partnerID=8YFLogxK

U2 - 10.1007/s12032-012-0251-7

DO - 10.1007/s12032-012-0251-7

M3 - Article

C2 - 22729365

AN - SCOPUS:84872820174

VL - 29

SP - 2095

EP - 2101

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 3

ER -